NCT01686217View on ClinicalTrials.gov

A Phase I Study to Compare 3 Different Strengths of an Extended Release Formulation of ASP015K to an Immediate Release Formulation of ASP015K

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions
Pharmacokinetics of ASP015KFood EffectHealthy Volunteers
Interventions
DRUG

ASP015K ER

oral extended release (ER) at three dosing levels

DRUG

ASP015K IR

oral immediate release (IR)

Trial Locations (1)

21225

Parexel International, Baltimore

All Listed Sponsors
lead

Astellas Pharma Global Development, Inc.

INDUSTRY

NCT01686217 - A Phase I Study to Compare 3 Different Strengths of an Extended Release Formulation of ASP015K to an Immediate Release Formulation of ASP015K | Biotech Hunter | Biotech Hunter